

Correction

Correction: Bone marrow involvement identifies a subgroup of advanced Ewing sarcoma patients with fatal outcome irrespective of therapy in contrast to curable patients with multiple bone metastases but unaffected marrow**Uwe Thiel¹, Angela Wawer¹, Irene von Luettichau¹, Hans-Ulrich Bender¹, Franziska Blaeschke¹, Thomas G.P. Grunewald², Marc Steinborn³, Barbara Röper^{4,10,*}, Halvard Bonig^{5,6}, Thomas Klingebiel⁵, Peter Bader⁵, Ewa Koscielniak⁷, Michael Paulussen⁸, Uta Dirksen⁹, Heribert Juergens⁹, Hans-Jochem Kolb¹ and Stefan E.G. Burdach^{1,10}**

¹Department of Pediatrics and Pediatric Oncology Center, Kinderklinik München Schwabing, Städtisches Klinikum München und Klinikum rechts der Isar, Wilhelm Sander Sarcoma Unit, Klinikum rechts der Isar, Technische Universität München, Munich, Germany

²Laboratory for Pediatric Sarcoma Biology, Institute of Pathology, LMU, Munich, Germany

³Department of Radiology, Klinikum Schwabing, Städtisches Klinikum München, Munich, Germany

⁴Department of Radiation Oncology, Klinikum rechts der Isar, Technische Universität München, Munich, Germany

⁵Department of Pediatric Hematology and Oncology, Universitätsklinikum Frankfurt, Frankfurt, Germany

⁶Department of Transfusion Medicine and Immunohematology, Universitätsklinikum Frankfurt, Frankfurt, Germany

⁷Department of Pediatric Oncology, Hematology and Immunology, Olgahospital, Klinikum Stuttgart, Stuttgart, Germany

⁸Vestische Kinder- und Jugendklinik, Datteln, Universität Witten/Herdecke, Datteln, Germany

⁹Department of Pediatric Hematology and Oncology, Universitätsklinikum Münster, Münster, Germany

¹⁰Munich Comprehensive Cancer Center, München, Germany

* Present address: Radiation Oncology Clinic, Klinikum Bogenhausen, Städtisches Klinikum München, Munich, Germany

Published:

Copyright: © 2022 Thiel et al. This is an open access article distributed under the terms of the [Creative Commons Attribution License](https://creativecommons.org/licenses/by/3.0/) (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

This article has been corrected: In the PATIENTS AND METHODS section, under the paragraph heading ‘Myeloablation and autologous stem cell transplantation,’ the text has been corrected as follows: ‘In MetaEICESS 2007 myeloablation consisted of melphalan (30 mg/m²/day on day -7 until -4 before first autologous stem cell transplantation) in combination with etoposide (1800 mg/m²/day on day -3 before first autologous stem cell transplantation) followed by application of topotecan (2 mg/m²/day on day -7 until -3 before second autologous stem cell transplantation) in combination with treosulfan (10 mg/m²/day on day -5 until -3 before second autologous stem cell transplantation).’ The authors declare that these corrections do not change the results or conclusions of this paper.

Original article: Oncotarget. 2016; 7:70959–70968. <https://doi.org/10.18632/oncotarget.10938>